After going ‘crazy’ over the science, Merck signs up a new partner in the hunt for an HIV cure
Less than a year after inking a $100 million licensing deal with German giant Bayer, Dewpoint Therapeutics has scored another big-time contract, this time with Merck. And this collaboration came together in a particularly unusual fashion.
Merck and Dewpoint have agreed on a partnership that will provide the pharma giant with access to the Boston-based biotech’s biomolecular condensate technology in order to develop treatments, and potentially a cure, for the HIV virus. Dewpoint, in turn, will receive up to $305 million in upfront and milestone payments as well as royalties for any approved product.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.